Immunovia publ AB (IMMNOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immunovia publ AB (IMMNOV) has a cash flow conversion efficiency ratio of -0.449x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-20.89 Million ≈ $-2.25 Million USD) by net assets (Skr46.50 Million ≈ $5.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Immunovia publ AB defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Immunovia publ AB - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Immunovia publ AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Immunovia publ AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunovia publ AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Picard Medical, Inc.
NYSE MKT:PMI
|
-1.155x |
|
CONX Corp
NASDAQ:CONX
|
0.026x |
|
Toleranzia AB
ST:TOL
|
-0.023x |
|
Great Northern Minerals Ltd
AU:GNM
|
-0.073x |
|
Sable Resources Ltd
V:SAE
|
-0.098x |
|
Schulte-Schlagbaum AG
DU:SSS
|
N/A |
|
Soditech SA
PA:SEC
|
0.053x |
|
Mayfield Childcare Ltd
AU:MFD
|
0.064x |
Annual Cash Flow Conversion Efficiency for Immunovia publ AB (2013–2025)
The table below shows the annual cash flow conversion efficiency of Immunovia publ AB from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Immunovia publ AB stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr64.73 Million ≈ $6.97 Million |
Skr-78.40 Million ≈ $-8.44 Million |
-1.211x | +85.42% |
| 2024-12-31 | Skr11.65 Million ≈ $1.25 Million |
Skr-96.75 Million ≈ $-10.41 Million |
-8.306x | -278.36% |
| 2023-12-31 | Skr66.99 Million ≈ $7.21 Million |
Skr-147.06 Million ≈ $-15.83 Million |
-2.195x | -204.81% |
| 2022-12-31 | Skr243.80 Million ≈ $26.24 Million |
Skr-175.58 Million ≈ $-18.90 Million |
-0.720x | -104.71% |
| 2021-12-31 | Skr433.90 Million ≈ $46.70 Million |
Skr-152.65 Million ≈ $-16.43 Million |
-0.352x | -74.70% |
| 2020-12-31 | Skr599.40 Million ≈ $64.51 Million |
Skr-120.70 Million ≈ $-12.99 Million |
-0.201x | +21.68% |
| 2019-12-31 | Skr357.61 Million ≈ $38.48 Million |
Skr-91.95 Million ≈ $-9.90 Million |
-0.257x | -41.22% |
| 2018-12-31 | Skr461.95 Million ≈ $49.71 Million |
Skr-84.11 Million ≈ $-9.05 Million |
-0.182x | +6.91% |
| 2017-12-31 | Skr236.80 Million ≈ $25.48 Million |
Skr-46.32 Million ≈ $-4.98 Million |
-0.196x | -355.98% |
| 2016-12-31 | Skr276.63 Million ≈ $29.77 Million |
Skr-11.87 Million ≈ $-1.28 Million |
-0.043x | -26.43% |
| 2015-12-31 | Skr83.80 Million ≈ $9.02 Million |
Skr-2.84 Million ≈ $-305.99K |
-0.034x | +85.37% |
| 2014-12-31 | Skr35.74 Million ≈ $3.85 Million |
Skr-8.29 Million ≈ $-892.20K |
-0.232x | -176.53% |
| 2013-12-31 | Skr4.94 Million ≈ $531.55K |
Skr-414.31K ≈ $-44.59K |
-0.084x | -- |
About Immunovia publ AB
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.